Home/ Stocks/ CGEN

Compugen Ltd

CGEN XNAS

$2.41 +0.11 (+4.78%) ▲ 15-min delayed

Open

$2.32

High

$2.43

Low

$2.31

Volume

275.8K

Market Cap

$217.54M

About Compugen Ltd

Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.

Employees: 75 Website →

Related Market News

No specific coverage for CGEN yet. Check out our latest market news or earnings calendar.

Get CGEN Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Compugen Ltd.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.